We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
When the news is actually confirmed this will be the launch pad to Thoths 28p before we head appreciably higher to £££'s. I have conducted my due diligence over the years and for me I am with Thoth, WIP, Afham, PhilBoro, AndyMc, Brighty, Stoney, steadydanny, RMM & co regarding Sareum heading to over a £1 a share. The billions spent on licencing and acquisitions in the pharmaceutical sector is what gives me the greatest certainty that the Sareum science is the real deal from both an investment and scientific point of view. I won't be selling any of my shares as it is unquestionably Sareum’s time to shine.
From North East, so no champagne corks popping when this pops
‘Let’s just get doon the toon for a few bottles of broon, Haway the lads!’
Exactly Basser as I posted earlier in the week re submarine patents (see below) it could well be about the patent having such a novel property that it gets multi licensed, Royalties etc...here was my post
Submarine Patent14 Oct 2021 19:01
I'm no expert on patents but did a bit of research. From what I understand we don't have to release its details as any company that uses is in effect paying royalties if their technology advancement finds a future use to said updated patent. Which can remain 'underwater. So this is a copy re submarine patents
The key difference between the pre-1995 17-year patent term and the current 20-year patent term is the start date. Currently, once you file a patent application the clock is ticking down on the 20 years. There are provisions to add some time to that 20-year calculation. These provisions mostly account for government delays like slow patent examination or hold-ups in the FDA approval process.
However, the 17-year patent term only starts when the patent actually issues. Therefore, when the patent examiner “allows” your patent application, you do not let it “grant.” That would start your 17-year term. Rather, you file a “continuation” to keep it “underwater” or “pending.” During this time, competitors develop and adopt the technology. Once the industry embraces the technology, you finally allow your submarine patent to “surface.” This starts your 17-year patent term. However, now the technology is ubiquitous and you have greater leverage to force a settlement or payout.
As in we have wet there whistle per sei and they will all be following the concept with their own r and d. But we hold the overall patent for anything they develop that is linked to our patent.
Question is which big pharma wants first hand access to the applicants/inventors and at what price? Bidding frenzy incoming? GSK needing scientific directors as per Elliot consternation of leadership? Or they copy the concept and if successful we get royalties.
This could well be a momentous occasion. Not just for sareum but for scientific research.
Best regards Steadydanny
Num- I would have thought that this includes Cancers as well re SD1802?
Great find timbo 003 and MADD- RIP. We need to tread carefully here but is appears that this is the process being patented. Quote from Patent “ The foregoing examples are presented for the purpose of illustrating the invention and should not be construed as imposing any limitations on the scope of the invention. It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications are intended to be embraced by this application”
All will be revealed in the inevitable RNS.
Madd, it's huge in the fact that it protects what could be multiple new drugs for treating autoimmune diseases. This is what will be the terms and conditions of a future deal and create the value. Handbrake needs to come off though now.
Hey Thoth, my time is not my own at the minute so struggling to keep up with the board, could be a good week ahead though. More milestones reached in this investment, the next one's should be huge.
As an imbecile in these fields, are we looking at something that is this huge?
Does it mean the compound allows many different medications to be transformed/created using this compound for use in tablet/inhaler form. Please excuse my ignorance btw. But I am glad for everyone if it is what you all believe it is. Gla
Nice to see you num4 ;). Timbo knows his patents and await his further analysis. Im looking for.
1. Uniqueness in tyk2 land
2. Could it be used for other drugs (nice royalty stream)
3. Inhaleable tyk2. That would be very very cute
Bear in mind. Bms sold orezla for $14bn because they thought the tyk2 they acquired was more valuable. Aim high my friends.
The lower the IC50 the better efficacy in inhibiting the target, which is tyk2, therefore if you only need a small amount of dosage for the required inhibition unwanted side effects should be minimal.
The lower the IC50 value, the more effective it is at lower concentrations, therefore less toxicity.
Evening Num4 - your ‘IC50 value of the new compound is 1.9 against Tyk2’ comment, is that good?
I was never any good at science at school
Never mind the value of Sareum, how much is John Reader worth?!
First time Sareum have listed people other than John on the patent, strange. They are all based in the good old North East, Cramlington and Sunderland.
IC50 value of the new compound is 1.9 Against TYK2.
Manufacturing sorted, the details are now out there and the new tyk2 is in town. Trials about to start and the longest patent protection for the compound. This could turn into the biggest breakthrough for autoimmune diseases, hoping the handbrake comes off this now. Good luck people